Author of

• 20167

  +

  P2.03 - Chemotherapy/Targeted Therapy (ID 704)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23313

    +

    P2.03-042 - EGFR Mutation and Erlotinib Efficacy in Turkish Oncoregistry (ID 9545)

    09:30 - 16:00  |  Presenting Author(s): Mahmut Gumus
    • Abstract
    • Slides

    Background:
    The aim of this registry was to collect demographic, diagnostic, treatment, and outcome information about Turkish patients with non-small cell lung cancer (NSCLC).
    
    Method:
    It was designed as a multicenter, cross-sectional, non-interventional study conducted on new and previously diagnosed lung cancer cases applied to 28 medical oncology outpatient clinics between 2012 and 2015. A total of 3790 male (85,5%) and female (14,5%) patients >18 years were included.
    
    Result:
    Mean age of patients was 60,4 (SD:±9,2) years. 79,4% of patients had smoking history and 19,6% of patients had familial cancer history. 63,5 % of patients were at stage IIIB and IV. 47,1% of total patients had adenocarcinoma and 42,2% had squamous cell carcinoma. In patients with no smoking history, adenocarcinoma histology was more dominant; 58,7% adenocarcinoma vs 30,6% squamous cell carcinoma. EGFR testing rate increased throughout the years but dependent to late market access of TKIs for EGFR mutation positive patients the testing rate for total patients is only 14,4%. EGFR mutation positivity rate in tested patients is 21,75% and 58,5% of these patients had exon 19 deletion. Overall survival of stage 4 patients was 15.9 months. For patients tested positive for EGFR mutation, erlotinib significantly improved the overall survival to 34,5 months (erlotinib users) vs 30,2 months (non-users) (p=0,043).
    
    Conclusion:
    In this multicenter, cross-sectional, non-interventional study we had an overall picture of Turkish NSCLC patients. 63,5% of NSCLC patients were at stage IIIB-IV and EGFR mutation positivity rate was 21,75%. For EGFR mutated patients, erlotinib is an effective treatment option and significantly improves overall survival.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.